Supplementary material for Chilala et al. Implementation of digital adherence technologies for tuberculosis treatment adherence: a systematic review and meta-analysis.

1	Onlin	e supplement Appendix 1	2
	1.1. F (PRISMA	Preferred Reporting Items for Systematic reviews and Meta-Analyses extension A) abstract checklist	. 2
	1.2. F Scoping	Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Reviews (PRISMA-ScR) checklist	. 4
2	Onlin	e supplement Appendix 2	8
	2.1.	Methods	8
	2.1.1.	PICOS	8
	2.1.2.	Summary of search terms	9
	2.1.3.	Complete list of search terms1	10
	2.1.4.	Inclusion and exclusion criteria2	24
	2.1.5.	RE-AIM framework for the DAT review2	26
	2.2.	Results2	28
	2.2.1.	Additional figures and tables2	28
	2.2.2.	References from which data were extracted for the scoping review	19
	2.3.	Supplement references	59

1. Online supplement Appendix 1

1.1. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension (PRISMA) abstract checklist

Section and Topic	ltem #	Checklist item	Reported (Yes/No)		
TITLE					
Title	1	Identify the report as a scoping review.	Yes		
BACKGROUND					
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes, last sentence of Introduction of Abstract		
METHODS					
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes, Methods section of Abstract, first sentence		
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes, Methods section of the Abstract - the number of databases used is described (details of the databases are in the main methods)		
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Not applicable for a scoping review		
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes, use of the RE-AIM framework to organise results		
RESULTS					

Section and Topic	ltem #	Checklist item	Reported (Yes/No)	
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes, Results section of Abstract, first two sentences	
Synthesis of results 8		 Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured). 		
DISCUSSION	_			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes, Results section of the Abstract, last sentence	
Interpretation	Interpretation10Provide a general interpretation of the results and important implications.		Yes, Conclusion section of the Abstract	
OTHER				
Funding	11	Specify the primary source of funding for the review.	Yes, this has been reported separately in the journal online system	
Registration	on12Provide the register name and registration number.Yes, this is remethodswethodsYesYes		Yes, this is reported in methods	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <u>http://www.prisma-statement.org/</u>

1.2. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #		
TITLE					
Title	1	Identify the report as a scoping review.	Reported on the title page		
ABSTRACT					
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	Reported in the Abstract. The PRISMA Abstract checklist has also been completed.		
INTRODUCTION	INTRODUCTION				
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	Introduction, paragraphs 2		
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	Introduction, paragraph 3		
METHODS					
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	Methods section, paragraph 1		

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	Methods section, paragraph 1, and Online supplementary appendix 1, table S1 (PICOS)
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	Methods section, subsection on "Search strategy"
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Online supplementary appendix 1, table S2
Selection of sources of evidence ⁺	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	Methods section, subsection on "Study screening and data extraction", 1 st paragraph; & 3
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	Methods section, subsection on "Study screening and data extraction", 2 nd paragraph
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Methods section, subsection on "Re-AIM framework"; and Online supplementary appendix 1, table S4
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	The methods describe the approach – initially planned as a systematic review, which was changed to a scoping review – justification given.
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	Methods section, entire subsection on "Analysis":

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #		
RESULTS					
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Results section, subsection on "Characteristics of the included studies," paragraph 1, Figure S1 (PRISMA flowchart), and Table 1; and table S10		
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Results section, subsection on "Characteristics of the included studies," paragraph 1 and Table 1		
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not done		
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Online supplementary tables S5-S9; & figure S2-S10, appendices 2 and 3, which provide details on findings from the sources of evidence that inform meta-themes for "reach" and "adoption"		
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Figures 1a, 1b, 2a, 2b, 3 Tables 2 And in the text of the results section – under each RE-AIM heading		
DISCUSSION	DISCUSSION				
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	Our findings for each of reach, adoption, implementation and maintenance are summarized in separate paragraphs		

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #	
Limitations	20	Discuss the limitations of the scoping review process.	Paragraph 6	
Conclusions 21 Provide a genera and/or next step:		Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Last paragraph of the discussion	
FUNDING				
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Funding section	

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).
‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data

The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi: 10.7326/M18-0850.

2. Online supplement Appendix 2

Additional methods and results to accompany the manuscript *Chilala et al. Implementation of digital adherence technologies for tuberculosis treatment adherence: a systematic review and meta-analysis.*

2.1. Methods

2.1.1. PICOS

Table S1. PICOS table – used to define the study question and identify eligible studies

Population	Individuals with active TB disease
	Individuals with latent TB infection
	All other individuals (e.g., healthcare providers, programs managers, or
	policymakers) who are involved in implementation of TB digital adherence
	technologies (DATs) within health systems.
	Individuals from both high-income and low- and middle-income country
	cottings
Intonyoption	Digital adherence technologies which can support monitoring TP modication
Intervention	Digital adherence technologies which can support monitoring TB medication
	adherence as an intervention being implemented. These technologies include
	feature phone and smartphone technologies, video-supported therapy, digital
	pillboxes, and ingestible sensors.
Comparator	The studies may or may not have had a control or comparison group.
Outcome	Reach (for patients): Number and proportion of the patients who engage with a
	DAT.
	Adoption (by providers or healthcare system): Number and proportion of
	healthcare providers who engage with the DAT,
	Implementation (by providers and healthcare system): Fidelity of the
	intervention refers to the extent to which the intervention is operated as
	intended
	Maintenance (by health system): The extent to which DATs become
	institutionalized as part of routine care
Study	Observational studies: These may include cohort case-control or cross-
design	sectional studies case series etc. These studies will be particularly important
uesign	for extracting data on RE AIM outcome measures
	Tor extracting data on RE-Aim outcome measures.
	Trials: These may include randomized trials and trials with a quasi-experimental
	design. These studies will be particularly important for extracting data on RE-
	AIM outcome measures.

2.1.2. Summary of search terms

Table S2. Summary of search terms.

Tuberculosis	exp tuberculosis/ OR TB OR
	exp mycobacterium tuberculosis/ OR MTB OR
	Kochs disease OR
	Phthisis OR
	drug resistant TB OR DR TB OR
	multidrug resistant TB OR MDRTB OR
	extensively drug resistant TB OR XDRTB OR XDR-TB OR
	latent TR infection OR LTRLOP
	Anti TB treatment OB Antitubercular Agents/ OB
	The answer to the stars the stars and OD TOT
DATS	(digital OR electronic* or virtual*) adj2 adherence) OR
	digital technolog* OR Digital health OR digital adherence technology OR DAT
	OR
	digital pill box* OR smart pill box
	digital medication monitor OR
	tele* OR tele-intervention OR telemonitor* OR teletherapy OR telehealth or
	teleassist* OR telebased OR tele-based OR telemedicine OR
	eHealth OR e health OR
	(virtual* or electronic* OR mobile or wireless) adi2 observ*) OR mhealth OR m
	health OR
	Wireless observed therapy OR WOT OR
	Vmalt OR
	MEMS OP Medication event monitoring system OP
	medical electronic monitoring OP
	menitoring concert OD
	Ingestible sensor*
	monitoring device* OR
	electronic medication package* OR
	electronic medication monitor OR
	medication event reminder monitor OR MERM OR
	Artificial intelligence OR
	(mobile adj (device* or health or phone*)) OR
	smartphone* or smart phone* OR
	cellphone* or cell phone* OR
	Mobile technology OR
	Or feature phone OR
	Cellular technology OR
	SMS OR short message service OR
	text messag* OR
	MMS OP multimodia massag* OP
	I WIWIS ON HIUILIHEUIA HESSAG OK
	video* OR videophone OR video observed therapy OR VOT OR

vdot OR video directly observed therapy OR video DOT OR
video supported therapy OR VST OR
Webcam* OR web cam* OR
web based OR health IT OR
health ICT

2.1.3. Complete list of search terms

Complete list of search terms: April 2022

MEDLINE on Ovid

Translated and exported to EndNote/RIS and documented and saved and linked

2470 records on April 14, 2022

Ovid MEDLINE(R) ALL <1946 to April 13, 2022>

1 exp tuberculosis/ or mycobacterium tuberculosis/ 223226

2 Antitubercular Agents/ 40109

3 (Tuberculosis or Kochs disease or Phthisis or TB or MTB or MDRTB or XDRTB or DRTB or LTBI or directly observed treatment short course).mp. 289886

4 1 or 2 or 3 [TB CONCEPT] 295272

5 ((antitubercular agents/ or directly observed therapy/ or medication adherence/ or patient compliance/ or "treatment adherence and compliance"/) and technology/) or mobile applications/ or internet/ or cell phone/ or smartphone/ or text messaging/ or computer, handheld/ or telemedicine/ or therapy, computer-assisted/ or medical informatics applications/ 139552

6 (((digital* or electronic* or mobile or wireless* or virtual*) adj2 (adherence or medication monitor* or medication package* or observ*)) or digital technolog* or technology-based or Digital health or eHealth or e health or mhealth or m health or SMS or reminder* or short messag* service* or text messag* or MMS or multimedia messag* or MEMS or (monitor* adj2 (electronic* or sensor* or device*)) or Webcam* or web cam* or smartphone* or smart phone* or web based or health IT or health ICT or ((cell* or mobile) adj1 (device* or health or phone* or technolog*)) or video* or cellphone* or feature phone* or vdot or vmalt or tele* or dat or wot or 99dots or 99 dots or monitoring system* or ingestible sensor* or merm or artificial intelligence or ai or vot or ((digital or smart) adj (pill box* or pillbox*)) or VST).mp. 639317

7 5 or 6 [DAT CONCEPT] 705189

8 4 and 7 [TB CONCEPT AND DAT CONCEPT] 2898

9 limit 8 to yr="2000 -Current" 2470

https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE =main&SHAREDSEARCHID=2l1i2gOeCS9cXwmAbalMaCHkWD4prRHR1lh5QIwVBJkM7ND1UnAQ7GLq y8sarvLiP

Embase on Ovid

Translated and exported to EndNote/RIS and documented and saved and linked

4363 records on April 14, 2022

Embase <1996 to 2022 Week 14>

1 exp tuberculosis/ or mycobacterium tuberculosis/ 189354

2 tuberculostatic agent/ 29551

3 (Tuberculosis or Kochs disease or Phthisis or TB or MTB or MDRTB or XDRTB or DRTB or LTBI or directly observed treatment short course).mp. 227443

4 1 or 2 or 3 [TB CONCEPT] 238274

5 ((tuberculostatic agent/ or directly observed therapy/ or medication compliance/ or patient compliance/) and technology/) or communication technology/ or exp mobile application/ or internet/ or web-based intervention/ or exp mobile phone/ or text messaging/ or personal digital assistant/ or telemedicine/ or exp teleconsultation/ or telemonitoring/ or video consultation/ or computer-assisted therapy/ or computer-assisted drug therapy/ or medical informatics/ 234981

6 (((digital* or electronic* or mobile or wireless* or virtual*) adj2 (adherence or medication monitor* or medication package* or observ*)) or digital technolog* or technology-based or Digital health or eHealth or e health or mhealth or m health or SMS or reminder* or short messag* service* or text messag* or MMS or multimedia messag* or MEMS or (monitor* adj2 (electronic* or sensor* or device*)) or Webcam* or web cam* or smartphone* or smart phone* or web based or health IT or health ICT or ((cell* or mobile) adj1 (device* or health or phone* or technolog*)) or video* or cellphone* or feature phone* or vdot or vmalt or tele* or dat or wot or 99dots or 99 dots or monitoring system* or ingestible sensor* or merm or artificial intelligence or ai or vot or ((digital or smart) adj (pill box* or pillbox*)) or VST).mp. 760427

- 7 5 or 6 [DAT CONCEPT] 869295
- 8 4 and 7 [TB CONCEPT AND DAT CONCEPT] 4511
- 9 limit 8 to yr="2000 -Current" 4363

https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE =main&SHAREDSEARCHID=4qmX18vJd91JLhFRKkCNbwQdXJ1kl6DMnZbzqSytTGbtPaLEivaR11twWrp JPqIU4

CINAHL on EBSCOhost

Translated and exported to EndNote/RIS and documented

1372 records on April 14, 2022

#	Query	Limiters/Expanders	Last Run Via	Results
\$9	S4 AND S7	Limiters - Published Date: 20000101- 20221231 Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	1,372
\$8	S4 AND S7	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	1,444
\$7	S5 OR S6	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	388,328
S6	(((digital* OR electronic* OR mobile OR wireless* OR virtual*) N2 (adherence OR "medication monitor*" OR "medication package*" OR observ*)) OR "digital technolog*" OR technology-based OR "Digital health" OR eHealth OR "e health" OR mhealth OR "m health" OR SMS OR reminder* OR "short messag* service*" OR "text messag*"	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search	325,900

OR MMS OR "multimedia messag*" OR MEMS OR (monitor* N2 (electronic* OR sensor* OR device*)) OR Webcam* OR "web cam*" OR smartphone* OR "smart phone*" OR "web based" OR "health IT" OR "health ICT" OR ((cell* OR mobile) N1 (device* OR health OR phone* OR technolog*)) OR video* OR cellphone* OR "feature phone*" OR vdot OR vmalt OR tele* OR dat OR wot OR 99dots OR "99 dots" OR "monitoring system*" OR "ingestible sensor*" OR merm OR "artificial intelligence" OR ai OR vot OR ((digital OR smart) W1 ("pill box*" OR pillbox*)) OR VST)

((MH "Antitubercular Agents") OR (MH "Directly Observed Therapy") OR (MH "Medication Compliance") OR (MH "Patient Compliance")) AND (MH "Technology")) OR (MH "Wireless Communications") OR (MH "Mobile Applications") OR (MH "Internet") OR (MH "Internet-Based Intervention") OR (MH "Cellular Phone+") OR (MH "Text Messaging+") OR (MH "Instant Messaging") OR (MH "Interactive Voice Response Systems") OR (MH "Videoconferencing+") OR (MH "Computers, Hand-Held+") OR (MH "Telehealth+") OR (MH "Digital Technology") OR (MH "Therapy, Computer Assisted") OR (MH "Drug Therapy, Computer Assisted") OR S5 (MH "Medical Informatics")

Database -**CINAHL Plus** with Full Text

Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	123,854
Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	37,720
	Interface -	

S4 S1 OR S2 OR S3

EBSCOhost (Tuberculosis OR "Kochs disease" OR Phthisis Expanders - Apply Research OR TB OR MTB OR MDRTB OR XDRTB OR equivalent subjects Databases DRTB OR LTBI OR "directly observed Search modes -Search S3 treatment short course") Boolean/Phrase 37,417 Screen -

			Advanced Search Database - CINAHL Plus with Full Text	
S2	(MH "Antitubercular Agents")	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	4,730
		Expanders - Apply	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database -	
		equivalent subjects	CINAHL Plus	
	(MH "Tuberculosis+") OR (MH	Search modes -	with Full	
S1	"Mycobacterium Tuberculosis")	Boolean/Phrase	Text	25,774

CENTRAL on Cochrane Library

Translated and exported to EndNote/RIS and documented

1908 records on April 14, 2022

Search Name:

Date Run: 14/04/2022 19:14:58

Comment:

ID Search Hits

#1(Tuberculosis or "Kochs disease" or Phthisis or TB or MTB or MDRTB or XDRTB or DRTB orLTBI or "directly observed treatment short course"):ti,ab,kw8527

#2 (((digital* or electronic* or mobile or wireless* or virtual*) NEAR/2 (adherence or medication NEXT monitor* or medication NEXT package* or observ*)) or digital NEXT technolog* or technology-based or "Digital health" or eHealth or "e health" or mhealth or "m health" or SMS or reminder* or short NEXT messag* NEXT service* or text NEXT messag* or MMS or multimedia NEXT messag* or MEMS or (monitor* NEAR/2 (electronic* or sensor* or device*)) or Webcam* or web NEXT cam* or smartphone* or smart NEXT phone* or "web based" or "health IT" or "health ICT" or ((cell* or mobile) NEXT (device* or health or phone* or technolog*)) or video* or cellphone* or feature NEXT phone* or vdot or vmalt or tele* or dat or wot or 99dots or 99 NEXT dots or monitoring NEXT system* or ingestible NEXT sensor* or merm or artificial NEXT intelligence or ai or vot or ((digital or smart) NEXT (pill box* or pillbox*)) or VST):ti,ab,kw 315245

#3 #1 AND #2 with Publication Year from 2000 to 2022, in Trials 1908

[No link provided]

SCI-EXP, CPCI-S, ESCI (Web of Science Core Collection)

Translated and exported to EndNote/RIS and documented and linked

Exact search

2527 records on April 14, 2022

TS=(Tuberculosis OR "Kochs disease" OR Phthisis OR TB OR MTB OR MDRTB OR XDRTB OR DRTB OR LTBI OR "directly observed treatment short course")

AND

TS=(((digital* OR electronic* OR mobile OR wireless* OR virtual*) NEAR/2 (adherence OR "medication monitor*" OR "medication package*" OR observ*)) OR "digital technolog*" OR technology-based OR "Digital health" OR eHealth OR "e health" OR mhealth OR "m health" OR SMS OR reminder* OR "short messag* service*" OR "text messag*" OR MMS OR "multimedia messag*" OR MEMS OR (monitor* NEAR/2 (electronic* OR sensor* OR device*)) OR Webcam* OR "web cam*" OR smartphone* OR "smart phone*" OR "web based" OR "health IT" OR "health ICT" OR ((cell* OR mobile) NEAR/1 (device* OR health OR phone* OR technolog*)) OR video* OR cellphone* OR "feature phone*" OR vdot OR vmalt OR tele* OR dat OR wot OR 99dots OR "99 dots" OR "monitoring system*" OR "ingestible sensor*" OR merm OR "artificial intelligence" OR ai OR vot OR ((digital OR smart) NEAR/0 ("pill box*" OR pillbox*)) OR VST)

2000-

https://www.webofscience.com/wos/woscc/summary/24ede919-4384-46a5-92ed-3100dc08594b-310dc79f/relevance/1

MedRxiv and other preprints via Europe PMC

Translated and exported to EndNote/RIS and documented

266 records on April 19, 2022

(TITLE:Tuberculosis OR TITLE:"Kochs disease" OR TITLE:Phthisis OR TITLE:TB OR TITLE:MTB OR TITLE:MDRTB OR TITLE:XDRTB OR TITLE:DRTB OR TITLE:LTBI OR TITLE:"directly observed treatment short course" OR TITLE: "antituberculosis" OR TITLE: "antituberculous") AND (Adher* OR "directly observed" OR Digital OR electronic OR internet OR mobile OR wireless OR virtual OR TITLE: technology OR "technology based" OR tele* OR ehealth OR "e health" OR mhealth OR "m health" OR SMS OR reminder* OR messaging OR message* OR MEMS OR web OR webcam* OR smartphone* OR "health IT" OR "health ICT" OR video* OR cellphone* OR phone* OR vdot OR vmalt OR dat OR wot OR 99dots OR "99 dots" OR "monitoring system" OR "monitoring systems" OR "ingestible sensor" OR "ingestible sensors" OR merm OR "artificial intelligence" OR AI OR VOT OR "smart pillbox" OR "smart pill box" OR VST OR "computer assisted") AND (SRC:PPR)

clinicaltrials.gov

Suggested

Condition or disease:

Tuberculosis OR Kochs disease OR Phthisis OR TB OR MTB OR MDRTB OR XDRTB OR DRTB OR LTBI OR directly observed treatment short course

Other terms:

Adherence OR directly observed OR computer OR Digital OR electronic OR internet OR mobile OR virtual OR technology OR video OR mhealth OR artificial intelligence OR AI OR cellphones OR SMS OR reminders OR monitoring OR MEMS OR DAT OR sensors

Complete list of search terms: April 2023

Database	Platform	Update date	# of records (total)	Notes
MEDLINE	Ovid	20230421 Note: If updating after this date, start at 20230419 for consistency	354 of 2793	Limited to ("20220414" or "20220415" or "20220416" or "20220417" or "20220418" or "20220419" or 2022042* or 2022043* or 202205* or 202206* or 202207* or 202208* or 202209* or 20221* or 2023*).dt,ez,da.
Embase	Ovid	20230421 Note: Results limited up to 20230419	661 of 5020	Limited to dc=20220414- 20230419

CINAHL	Cochrane Library/Wiley	20230419	146 of 857	Limited to EM 20220414- OR ZD "in process"
CENTRAL	EBSCOhost	20230419	196 of 2118	Date added to CENTRAL trials database Custom Range: 14/04/2022 to 19/04/2023
SCI-EXPANDED, CPCI-S, ESCI	Web of Science Core Collection	20230419	329 of 2863	Limited by Index date range 2022-04-14 to 2023-04-19
Preprints	Europe PMC	20230419	114 of 380	CREATION_DATE:[2022- 04-19 TO 2023-04-19] Search only includes concepts of TB and DATs
			1,800	TOTAL

MEDLINE (Ovid)

Ovid MEDLINE(R) ALL <1946 to April 20, 2023>

1 exp tuberculosis/ or mycobacterium tuberculosis/ 228085

2 Antitubercular Agents/ 41252

3 (Tuberculosis or Kochs disease or Phthisis or TB or MTB or MDRTB or XDRTB or DRTB or LTBI or directly observed treatment short course).mp. 300942

4 1 or 2 or 3 [TB CONCEPT] 306368

5 ((antitubercular agents/ or directly observed therapy/ or medication adherence/ or patient compliance/ or "treatment adherence and compliance"/) and technology/) or mobile applications/ or internet/ or cell phone/ or smartphone/ or text messaging/ or computer, handheld/ or telemedicine/ or therapy, computer-assisted/ or medical informatics applications/ 148180

6 (((digital* or electronic* or mobile or wireless* or virtual*) adj2 (adherence or medication monitor* or medication package* or observ*)) or digital technolog* or technology-based or Digital health or eHealth or e health or mhealth or m health or SMS or reminder* or short messag* service* or text messag* or MMS or multimedia messag* or MEMS or (monitor* adj2 (electronic* or sensor* or device*)) or Webcam* or web cam* or smartphone* or smart phone* or web based or health IT or health ICT or ((cell* or mobile) adj1 (device* or health or phone* or technolog*)) or video* or cellphone* or feature phone* or vdot or vmalt or tele* or dat or wot or 99dots or 99 dots or monitoring system* or ingestible sensor* or merm or artificial intelligence or ai or vot or ((digital or smart) adj (pill box* or pillbox*)) or VST).mp. 705541

- 7 5 or 6 [DAT CONCEPT] 772972
- 8 4 and 7 [TB CONCEPT AND DAT CONCEPT] 3221

9 limit 8 to yr="2000 -Current" 2793

10 ("20220414" or "20220415" or "20220416" or "20220417" or "20220418" or "20220419" or 2022042* or 2022043* or 202205* or 202206* or 202207* or 202208* or 202209* or 20221* or 2023*).dt,ez,da. 1903196

11 9 and 10 354

https://proxy.library.mcgill.ca/login?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE =main&SHAREDSEARCHID=3fnvVdcJME85FE7alzUoGwgVxZWFQGclstIdKYE9CMQFMhddHUd1jxgKm o1hQDBKW

Embase (Ovid)

Embase <1996 to 2023 Week 15>

1 exp tuberculosis/ or mycobacterium tuberculosis/ 204337

2 tuberculostatic agent/ 30987

3 (Tuberculosis or Kochs disease or Phthisis or TB or MTB or MDRTB or XDRTB or DRTB or LTBI or directly observed treatment short course).mp. 246187

4 1 or 2 or 3 [TB CONCEPT] 257637

5 ((tuberculostatic agent/ or directly observed therapy/ or medication compliance/ or patient compliance/) and technology/) or communication technology/ or exp mobile application/ or internet/ or web-based intervention/ or exp mobile phone/ or text messaging/ or personal digital assistant/ or telemedicine/ or exp teleconsultation/ or telemonitoring/ or video consultation/ or computer-assisted therapy/ or computer-assisted drug therapy/ or medical informatics/ 261570

6 (((digital* or electronic* or mobile or wireless* or virtual*) adj2 (adherence or medication monitor* or medication package* or observ*)) or digital technolog* or technology-based or Digital health or eHealth or e health or mhealth or m health or SMS or reminder* or short messag* service* or text messag* or MMS or multimedia messag* or MEMS or (monitor* adj2 (electronic* or sensor* or device*)) or Webcam* or web cam* or smartphone* or smart phone* or web based or health IT or health ICT or ((cell* or mobile) adj1 (device* or health or phone* or technolog*)) or video* or cellphone* or feature phone* or vdot or vmalt or tele* or dat or wot or 99dots or 99 dots or monitoring system* or ingestible sensor* or merm or artificial intelligence or ai or vot or ((digital or smart) adj (pill box* or pillbox*)) or VST).mp. 870210

- 7 5 or 6 [DAT CONCEPT] 984663
- 8 4 and 7 [TB CONCEPT AND DAT CONCEPT] 5167
- 9 limit 8 to yr="2000 -Current" 5020
- 10 limit 9 to dc=20220414-20230419 661

https://proxy.library.mcgill.ca/login?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE =main&SHAREDSEARCHID=7KKR39ofVynipL3CX0ToO3GWb5GrsIsDhbjFanUYdIRYp9ugDOcxhfduODO tnrlX1

CINAHL (EBSCOhost)

#	Query	Limiters/Expanders	Last Run Via	Results
S11	S9 AND S10	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	146
S10	EM 20220414- OR ZD "in process"	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	1,147,669
\$9	S4 AND S7	Limiters - Published Date: 20000101- 20231231 Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	857

S8	S4 AND S7	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	916
S7	S5 OR S6	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	347,115
56	(((digital* OR electronic* OR mobile OR wireless* OR virtual*) N2 (adherence OR "medication monitor*" OR "medication package*" OR observ*)) OR "digital technolog*" OR technology-based OR "Digital health" OR eHealth OR "e health" OR mhealth OR "m health" OR SMS OR reminder* OR "short messag* service*" OR "text messag*" OR MMS OR "multimedia messag*" OR MEMS OR (monitor* N2 (electronic* OR sensor* OR device*)) OR Webcam* OR "web cam*" OR smartphone* OR "smart phone*" OR "web based" OR "health IT" OR "health ICT" OR ((cell* OR mobile) N1 (device* OR health OR phone* OR technolog*)) OR video* OR cellphone* OR "feature phone*" OR vdot OR vmalt OR tele* OR dat OR wot OR 99dots OR S99 dots OR "monitoring system*" OR "ingestible sensor*" OR merm OR "artificial intelligence" OR ai OR vot OR ((digital OR smart) W1 ("pill box*" OR nillbox*)) OR VST)	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full	278 594

\$55	((MH "Antitubercular Agents") OR (MH "Directly Observed Therapy") OR (MH "Medication Compliance") OR (MH "Patient Compliance")) AND (MH "Technology")) OR (MH "Wireless Communications") OR (MH "Mobile Applications") OR (MH "Internet") OR (MH "Internet-Based Intervention") OR (MH "Cellular Phone+") OR (MH "Text Messaging+") OR (MH "Instant Messaging") OR (MH "Instant Messaging") OR (MH "Interactive Voice Response Systems") OR (MH "Videoconferencing+") OR (MH "Computers, Hand-Held+") OR (MH "Telehealth+") OR (MH "Digital Technology") OR (MH "Therapy, Computer Assisted") OR (MH "Drug Therapy, Computer Assisted") OR (MH "Medical Informatics")	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	133,190
S4	S1 OR S2 OR S3	Expanders - Apply equivalent subjects Search modes - Boolean/Phrase	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full Text	39,412
	(Tuberculosis OR "Kochs disease" OR	Expanders - Apply	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database -	
S3	Phthisis OR TB OR MTB OR MDRTB OR XDRTB OR DRTB OR LTBI OR "directly observed treatment short course")	equivalent subjects Search modes - Boolean/Phrase	CINAHL Plus with Full Text	39,091
			Interface - EBSCOhost	
S2	(MH "Antitubercular Agents")	Expanders - Apply equivalent subjects	Research Databases	4,883

Во	polean/Phrase	Screen - Advanced Search Database - CINAHL Plus with Full Text	
Ex eq rculosis+") OR (MH Se erium Tuberculosis") Bc	panders - Apply Juivalent subjects Parch modes -	Interface - EBSCOhost Research Databases Search Screen - Advanced Search Database - CINAHL Plus with Full	26 642

(MH "Tuber S1 "Mycobacte

CENTRAL (Cochrane Library/Wiley)

Search Name:

Date Run: 19/04/2023 19:42:11

Comment:

ID Search Hits

#1 (Tuberculosis or "Kochs disease" or Phthisis or TB or MTB or MDRTB or XDRTB or DRTB or LTBI or "directly observed treatment short course"):ti,ab,kw 9141

#2 (((digital* or electronic* or mobile or wireless* or virtual*) NEAR/2 (adherence or medication NEXT monitor* or medication NEXT package* or observ*)) or digital NEXT technolog* or technology-based or "Digital health" or eHealth or "e health" or mhealth or "m health" or SMS or reminder* or short NEXT messag* NEXT service* or text NEXT messag* or MMS or multimedia NEXT messag* or MEMS or (monitor* NEAR/2 (electronic* or sensor* or device*)) or Webcam* or web NEXT cam* or smartphone* or smart NEXT phone* or "web based" or "health IT" or "health ICT" or ((cell* or mobile) NEXT (device* or health or phone* or technolog*)) or video* or cellphone* or feature NEXT phone* or vdot or vmalt or tele* or dat or wot or 99dots or 99 NEXT dots or monitoring NEXT system* or ingestible NEXT sensor* or merm or artificial NEXT intelligence or ai or vot or ((digital or smart) NEXT (pill box* or pillbox*)) or VST):ti,ab,kw 359210

#3 #1 AND #2 with Publication Year from 2000 to 2023, in Trials 2118

Date added to CENTRAL trials database

Custom Range: 14/04/2022 to 19/04/2023

196 of 2118 records

WOS.SCI,WOS.ISTP,WOS.ESCI (Web of Science Core Collection)

Web of Science Search Strategy (v0.1)

Search: TS=(Tuberculosis OR "Kochs disease" OR Phthisis OR TB OR MTB OR MDRTB OR XDRTB OR DRTB OR LTBI OR "directly observed treatment short course")

AND

TS=(((digital* OR electronic* OR mobile OR wireless* OR virtual*) NEAR/2 (adherence OR "medication monitor*" OR "medication package*" OR observ*)) OR "digital technolog*" OR technology-based OR "Digital health" OR eHealth OR "e health" OR mhealth OR "m health" OR SMS OR reminder* OR "short messag* service*" OR "text messag*" OR MMS OR "multimedia messag*" OR MEMS OR (monitor* NEAR/2 (electronic* OR sensor* OR device*)) OR Webcam* OR "web cam*" OR smartphone* OR "smart phone*" OR "web based" OR "health IT" OR "health ICT" OR ((cell* OR mobile) NEAR/1 (device* OR health OR phone* OR technolog*)) OR video* OR cellphone* OR "feature phone*" OR vdot OR vmalt OR tele* OR dat OR wot OR 99dots OR "99 dots" OR "monitoring system*" OR "ingestible sensor*" OR merm OR "artificial intelligence" OR ai OR vot OR ((digital OR smart) NEAR/0 ("pill box*" OR pillbox*)) OR VST)

Editions: WOS.SCI, WOS.ISTP, WOS.ESCI

Timespan: 2000-01-01 to 2023-04-19

Date Run: Fri Apr 21 2023 14:19:23 GMT-0400 (Eastern Daylight Time)

Results: 2863

Database: Web of Science Core Collection

Entitlements:

- WOS.IC: 1993 to 2023
- WOS.CCR: 1985 to 2023
- WOS.SCI: 1900 to 2023
- WOS.AHCI: 1975 to 2023
- WOS.BHCI: 2005 to 2023
- WOS.BSCI: 2005 to 2023
- WOS.ESCI: 2005 to 2023
- WOS.ISTP: 1990 to 2023
- WOS.SSCI: 1900 to 2023

- WOS.ISSHP: 1990 to 2023

Searches:

Search:

#1

Timespan: 2022-04-14 to 2023-04-19

Date Run: Fri Apr 21 2023 14:20:33 GMT-0400 (Eastern Daylight Time)

Results: 329

MedRxiv and other preprints via Europe PMC

(TITLE:Tuberculosis OR TITLE:"Kochs disease" OR TITLE:Phthisis OR TITLE:TB OR TITLE:MTB OR TITLE:MDRTB OR TITLE:XDRTB OR TITLE:DRTB OR TITLE:LTBI OR TITLE:"directly observed treatment short course" OR TITLE:"antituberculosis" OR TITLE:"antituberculous") AND (Adher* OR "directly observed" OR Digital OR electronic OR internet OR mobile OR wireless OR virtual OR TITLE:technology OR "technology based" OR tele* OR ehealth OR "e health" OR mhealth OR "m health" OR SMS OR reminder* OR messaging OR message* OR MEMS OR web OR webcam* OR smartphone* OR "health IT" OR "health ICT" OR video* OR cellphone* OR phone* OR vdot OR vmalt OR dat OR wot OR 99dots OR "99 dots" OR "monitoring system" OR "monitoring systems" OR "ingestible sensor" OR "ingestible sensors" OR merm OR "artificial intelligence" OR AI OR VOT OR "smart pillbox" OR "smart pill box" OR VST OR "computer assisted") AND (SRC:PPR) AND CREATION_DATE:[2022-04-19 TO 2023-04-19]

2.1.4. Inclusion and exclusion criteria

Table S3. inclusion/exclusion criteria.

Inclusion criteria	Exclusion Criteria
Studies that address either active TB disease or latent TB infection in humans	Studies don't involve use of digital health interventions for tuberculosis treatment support.
Involve use of digital adherence technologies (DATs) in research or routine implementation	If the same study with the same outcomes has been reported by different papers, the most recent published paper will be included.
Studies that report data on implementation of DATs relevant to at least one dimension of the RE-AIM framework (excluding effectiveness)	Situations in which the abstract, paper, or report does not contain sufficient information to extract.

All observational studies (cohort studies, cross sectional studies, case-control studies), trials (randomized controlled	Editorials or review articles that do not present any primary research findings.
trials)	
Relevant abstracts and grey literature	
High-quality data from recent initiatives such as TB REACH	

2.1.5. RE-AIM framework for the DAT review

Table S4. RE-AIM framework.

RE-AIM DOMAIN	Definition	Categories	Description	Detail
Reach	Number and proportion of the patients who engage with a DAT, and related contextual	Category A – People with TB or taking LTBI with potential to use or receive DATs	Among all people with TB/ taking LTBI, the proportion (n/N) deemed eligible to receive DATs.	People who fall into the gap in category A may not be able to use DATs due to lack of phone access, severity of TB illness or hospital admission, for example.
	factors	Category B – People with TB with any uptake of, or engagement with, DATs	Among people who are eligible to receive DATs, the proportion provided DATs OR the proportion who exhibit any engagement after having been provided DATs: B1: proportion agreeing to use DAT, among those eligible B2: proportion engaged with DAT at least once, among those who started. B3: proportion with early engagement (over a shorter time period than entire treatment length)	People who fall into the gap may have been eligible for DATs by TB program guidelines but not actually provided with DATs, OR they may have been provided with DATs but not actually ever use the DAT (e.g., never calling 99DOTS, sending back a SMS to report a dose, opening the pillbox, etc.). We will also include, for example, measures that look at any engagement within the first one or two months.
		REACH Category C – Quality and/or duration of engagement with DATs	Among people who are provided with DATs, the proportion who exhibit various levels or durations of use over the treatment course. C1 Binary indicator (% pts with at least xx% engagement) C2 Dose-level - % engagement with DAT C3 % pts who stopped using DAT (excludes deaths, LTFU)	Measures may look at overall engagement measured as (i) a percentage DAT engagement over total dose-days or (ii) percentage of patients with DAT engagement >threshold. May look at the duration over which patients engaged (i.e., based on when patients stopped calling).

Adoption	Number and proportion of healthcare providers who engage with the DAT, and related contextual factors.	-	the proportion of providers who have the potential to engage with the DAT intervention	
Implementation	Fidelity of the intervention refers to the extent to which the intervention is operated as intended .	Implementation Technology fidelity	Ability of the technology (DAT) to function as it was intended to.	Factors relating to network coverage, battery problems, etc.
		Implementation Provider fidelity	 Consistency and delivery of the healthcare providers to the intervention, as was intended. 	Delivery of DAT counselling to patients, regular review of adherence data, appropriate outreach to patients, shifting of patients back to DOT/intensive management if required.
Maintenance	The extent to which DATs become institutionalized as part of routine care.		Long term uptake and sustainment	

2.2. Results

2.2.1. Additional figures and tables

Figure S1 - PRISMA Flow diagram of how papers were selected for inclusion into the analysis.



PRISMA Flow Diagram for the Implementation of DATs in TB using the RE-AIM framework

Author	Description of numerator	Description of denominator	n	N	%
Liu 2015	Number of PWTB who were deemed unable to use SMS texting or pillbox due to communication impairment	Number of PWTB approached for the trial across all study arms	191	6203	3%
Zelnick 2021	Number of prisoners, those lacking capacity, severe hearing impairment	enrolled plus numerator	21	221	9.5%
Wang 2020	Number of PWTB not eligible due to communication impairment	all PWTB registered for TB	162	2294	7%
Wang 2019	Number of PWTB who did not start pillbox due to communication impairment	Number of PWTB who were eligible for the pillbox	7	316	2%
Cattamanchi 2021	Number of PWTB excluded due to being too sick or elderly	total number of PWTB enrolled	18	891	2%

Table S5: summary of people with TB excluded from intervention due to communication impairment (Reach A)

PWTB person with TB; SMS short message service

Figure S2. Proportion sharing phone, of everyone with access to a phone (unplanned data collection)



Footnote: Multiple records for Guzman reflect different countries from this multi-country study. Two studies, Musiimenta (2020) & Saunders (2018), included in the unplanned data collection did not

have data on shared phone access. The proportion of people of owned phones were 89% (47/53) and 82% (2177/2655) respectively.

DAT type and				Proportion
Author (year)	n	Ν		(95% CI)
Pillbox				
Liu (2015)	12	1020 -	_	0.01 (0.01, 0.02)
Liu 1 (2015)	11	1094 🔶	_	0.01 (0.01, 0.02)
Wang (2019)	19	205	-	0.09 (0.06, 0.14)
Liu (2023)	106	1298	+	0.08 (0.07, 0.10)
SMS				
Mohammed (2012)	1	30 —		- 0.03 (0.00, 0.17)
Liu (2015)	15	1041 -	►	0.01 (0.01, 0.02)
		0		l .2

Figure S3. Proportion of PWTB electing to stop using the DAT for reasons other than death or lost to follow-up

Footnote: 1. proportion stopped using the combined pillbox and SMS DAT reported under pillbox

SMS short message service

Excluded from the plot: Casalme - 43/110 (39%) stopped using vide-supported therapy (VST) prior to the treatment outcome - 26/42 moved back to DOT based on HCP/patient decision - reasons included a preference for DOT or other synchronous VST, persistent non-adherence, broken phone, change of treatment centre.

Author	Year	DAT	Setting	Patient or dose- day level [n*]	Description of Measure	Numerator	Denominator	%
Cross	2019	99DOTS	LMIC	PWTB	% engagement on day 1		20469	74.0%
Cross	2019	99DOTS	LMIC	PWTB	% engagement on day 84		20469	60.0%
Cross	2019	99DOTS	LMIC	PWTB	% engagement on day 167		20469	56.0%
Thomas	2020	99DOTS	LMIC	PWTB	% engagement in the continuation phase	252	394	64.0%
Thomas	2020	99DOTS	LMIC	PWTB	% engagement in the intensive phase	144	203	70.9%
Subbaraman	2021	99DOTS	LMIC	РШТВ	% with 3/3 days of non-engagement (patient-reported doses)	191	608	31.4%
Subbaraman	2021	99DOTS	LMIC	PWTB	% with 3/3 days of non-engagement (patient- and provider-reported doses)	68	608	11.2%
Zhadnova	2020	phone	UMIC	PWTB	% daily DAT responses, in the first 2 months	27	44	61.4%
Zhadnova	2020	phone	UMIC	РШТВ	% responded to the DAT once every 3-7 days, in the first 2 months	17	44	38.6%
Story	2019	VST	HIC	PWTB	% who engage with DAT for at least 1 week	101	112	90.2%
Holzman	2019	VST	LMIC	РШТВ	% who satisfied the 10-day run-in period which evaluated their ability to record and submit videos	25	35	71.4%
Kiwanuka	2022	99DOTS	LIC	dose-day [n=456]	median % of dose-days with engagement, during the first month			71.4%
Kiwanuka	2022	99DOTS	LIC	dose-day [n=412]	median % of dose-days with engagement, during the sixth month			46.4%

Table S6: summary of other measures of DAT engagement (Reach B)

Muyindike	2022	pillbox	LIC	dose-day [n=275]	mean % of dose-days with engagement in the previous 90 days at 3 months			89.0%
Muyindike	2022	pillbox	LIC	dose-day [n=264]	mean % of dose-days with engagement in the previous 90 days at 6 months			81.0%
Wei	2023	pillbox	UMIC	PWTB	% with >80% DAT engagement in month 1	141	142	99.3%
Wei	2023	pillbox	UMIC	PWTB	% with >80% DAT engagement in month 2	140	142	98.6%

* n represents the number of participants contributing to the dose-day measure; PWTB person with TB; VST video-supported therapy; LIC low-income country, LMIC lowmiddle income country; UMIC upper-middle income country; HIC high-income country; DAT digital adherence technology

Cubarous and					Droportion 9/
Subgroup and Author (year)	n	N			(95% CI) Weight
					(
>99% van den Boogeard(2011)	14	47			0.30 (0.17, 0.45) 10.79
Mohammed(2012)	2	30	↓		0.07 (0.01, 0.22) 12 53
Bassett(2016)	400	967	• i 🔺		0.41 (0.38, 0.45) 14.29
Wang(2019)	61	154	· · · · · · · · · · · · · · · · · · ·	-	0.40 (0.32, 0.48) 12.99
Ratchakit-Nedsuwan(2020)	14	40	•	_	0.35 (0.21, 0.52) 10.06
Subbaraman(2021)	138	608	→ ¹ ¹		0.23 (0.19, 0.26) 14.25
Louwagie(2022)	99	283	· •		0.35 (0.29, 0.41) 13.71
Acosta(2022)	11	49			0.22 (0.12, 0.37) 11.38
Subgroup, DL		2178	\sim		0.29 (0.21, 0.38)100.00
(l ² = 89.8%, p < 0.000)					
>95%					
van den Boogaard(2011)	37	47		<u>_</u>	0.79 (0.64, 0.89) 31.08
Guo(2020)	148	235			0.63 (0.56, 0.69) 38.85
Ratchakit-Nedsuwan(2020)	32	40			0.80 (0.64, 0.91) 30.06
Subgroup, DL		322			0.73 (0.61, 0.85)100.00
(l ² = 89.8%, p < 0.000)					
>90%					
Garfein(2015)	43	51			0.84 (0.71, 0.93) 13.07
Wang(2019)	152	154		· · · · ·	0.99 (0.95, 1.00) 15.24
Guo(2020)	169	235			0.72 (0.66, 0.78) 14.50
Ratchakit-Nedsuwan(2020)	37	40		· · · · ·	0.93 (0.80, 0.98) 13.74
O'Donnell(2022)	145	198		—	0.73 (0.66, 0.79) 14.38
Acosta(2022)	48	49			0.98 (0.89, 1.00) 14.92
Wei(2023)	110	142			0.77 (0.70, 0.84) 14.16
Subgroup, DL		869			0.85 (0.76, 0.95)100.00
(l ² = 89.8%, p < 0.000)					
>85%					
Guo(2020)	186	235		- !	0.79 (0.73, 0.84) 34.29
Ratchakit-Nedsuwan(2020)	38	40			0.95 (0.83, 0.99) 31.62
Zelnick(2021)	163	198			0.82 (0.76, 0.87) 34.09
Subgroup, DL		473			0.85 (0.77, 0.94)100.00
(l ² = 89.8%, p < 0.000)					
>80%					
van den Boogaard(2011)	46	47		· · · · · · · · · · · · · · · · · · ·	0.98 (0.89, 1.00) 26.44
Story(2019)	78	122		—	0.64 (0.55, 0.72) 24.38
Ratchakit-Nedsuwan(2020)	39	40			0.97 (0.87, 1.00) 26.19
Rajalahti(2022)	27	30			0.90 (0.73, 0.98) 23.00
Subgroup, DL		239			0.88 (0.75, 1.01)100.00
(l ² = 89.8%, p < 0.000)					
>75%					
Mohammed(2012)	12	30			0.40 (0.23, 0.59) 48.42
Guo(2020)	209	235		· -	0.89 (0.84, 0.93) 51.58
Subgroup, DL (1 ² = 89.8%, p < 0.000)		265			0.65 (0.17, 1.13)100.00
>60%		100			0.77 /0.00 0.000
Narasimhan(2014)	77	100			0.77 (0.68, 0.85)100.00
Subgroup, DL		100			0.77 (0.68, 0.85)100.00
(l' = 89.8%, p < 0.000)					
>50%				A 1	
Mohammed(2012)	17	30	_		0.57 (0.37, 0.75) 13.09
Guo(2020)	228	235		2	0.97 (0.94, 0.99) 44.31
Garfein(2020)	143	149			0.96 (0.91, 0.99) 42.60
Subgroup, DL		414			0.91 (0.84, 0.99)100.00
(I" = 89.8%, p < 0.000)					

Engagement with a digital adherence technology by levels of engagement

NOTE: Weights and between-subgroup heterogeneity test are from random-effects model; continuity correction applied to studies with zero cells

Footnote		
Level of engagement	# of studies	# of persons
threshold		with TB
>99%	8	2178
>95%	3	322
>90%	7	869
>85%	3	473
>80%	4	239
>75%	2	265
>60%	1	100
>50%	3	414

Subgroup analyses.

Subgroup analysis, looking at levels of engagement, by DAT-type.

Figure S5. Sustained engagement with a DAT by levels of engagement - SMS

Subgroup and				Proportion		
Author (year)	n	Ν		(95% CI)		
>99%						
Mohammed(2012)	2	30	_ +	0.07 (0.01, 0.22)		
Bassett(2016)	400	967	~	0.41 (0.38, 0.45)		
Louwagie(2022)	99	283		0.35 (0.29, 0.41)		
>75%						
Mohammed(2012)	12	30		0.40 (0.23, 0.59)		
>50%						
Mohammed(2012)	17	30		0.57 (0.37, 0.75)		
			.2 .4 .6 .8	1		
Engagement with a SMS DAT by levels of engagement						

Subgroup and					Proportion
Author (year)	n	Ν			(95% CI)
>99%					
van den Boogaard(2011)	14	47			0.30 (0.17, 0.45
Wang(2019)	61	154			0.40 (0.32, 0.48
Ratchakit-Nedsuwan(2020)	14	40	—		0.35 (0.21, 0.52
Acosta(2022)	11	49			0.22 (0.12, 0.37
>95%					
van den Boogaard(2011)	37	47		—	0.79 (0.64, 0.89
Ratchakit-Nedsuwan(2020)	32	40		\$	0.80 (0.64, 0.91
>90%					
Wang(2019)	152	154		-	0.99 (0.95, 1.00
Ratchakit-Nedsuwan(2020)	37	40			0.93 (0.80, 0.98
O'Donnell(2022)	145	198			0.73 (0.66, 0.79
Acosta(2022)	48	49			 0.98 (0.89, 1.00
Wei(2023)	110	142			0.77 (0.70, 0.84
>85%					
Ratchakit-Nedsuwan(2020)	38	40			- 0.95 (0.83, 0.99
Zelnick(2021)	163	198			0.82 (0.76, 0.87
>80%					
van den Boogaard(2011)	46	47			 0.98 (0.89, 1.00
Ratchakit-Nedsuwan(2020)	39	40		•	- 0.97 (0.87, 1.00
			1 1	1 1	1

Figure S6. Sustained engagement with a DAT by levels of engagement - Pillbox

Engagement with a Pillbox DAT by levels of engagement

Figure S7. Sustained engagement with a DAT by levels of engagement – 99DOTS



NOTE: Continuity correction applied to studies with zero cells

Figure S8. Sustained engagement with a DAT by levels of engagement - VST



Engagement with a VST DAT by levels of engagement

Figure S9. Sustained engagement with a DAT by levels of engagement - Phone



Engagement by treatment phase

Considering engagement by treatment phase, where measures of DAT engagement over time were presented, these are summarised in Table S7. We found very few studies that showed engagement over different treatment phases.

Author	Year	Description of the measure	n	Ν	%
Intensive phase					
Moulding	2002	Proportion of individuals with >90% adherence in the first 11 weeks.	74	106	70%
Moulding	2002	Proportion of individuals with >80% adherence in the first 11 weeks.	92	106	87%
<u>Continuation</u> phase					
Moulding	2002	Proportion of individuals with >90% adherence in months 4-12.	62	106	58%
Moulding	2002	Proportion of individuals with >80% adherence in months 4-12.	88	106	83%
Menzies	2005	Proportion of patients who took >80% of doses within 20 weeks for 4RMP or 43 weeks for 9INH (latent tuberculosis tretament).	86	104	83%
Louwagie	2022	Proportion of patients with optimal adherence (assessed using adherence index using recall) over the last 4 days at 3 months of treatment.	319	348	92%
Louwagie	2022	Proportion of patients with optimal adherence (assessed using adherence index using recall) over the last 4 days at 6 months of treatment.	120	348	34%

Table S7. Varied measures of engagement with a DAT by treatment phase (Reach C)

Table S8. Varied measures of sustained engagement (Reach C).

Author	Year	Description of numerator	Description of denominator	n	N	%
Acosta	2022	Number of doses that were after the scheduled hour.	total # doses (from 49 PWTB)	586	2569	23%

Bachina	2022	Number of doses observed by VST	total # of prescribed doses (from 49 PWTB)	40	49	81%
Bachina	2022	PWTB who used VST post-COVID	total # PWTB post covid	12	18	67%
Bachina	2022	PWTB who used VST pre-COVID	total # PWTB pre covid	11	31	35%
Burhan	2019	Number of PWTB using the app at the end of the 3-month period.	# PWTB in the study	10	45	22%
Casalme	2022	Number of PWTB who stayed on VST until end of treatment.	Number of PWTB in VST group	67	110	61%
Chen	2020	Number of PWTB withdrawing from the programme.	# PWTB choosing VST	4	80	5%
Cross	2019	Number of PWTB who made a call on day 167 or later.	Number of PWTB on treatment at day 167.	13	20	65%
O'Donnell	2022	Number of PWTB with > 90% adherence.	Total number of PWTB.	145	198	73%
Trajman	2010	Number of PWTB with complete and reliable pillbox records to analyze adherence.	Number of PWTB in the study without medication adverse effects who had their adherence analyzed.	676	802	84%
Zelnick	2021	Number of PWTB with >85% adherence to Bedaquiline as measured by a DAT.	Number of PWTB enrolled.	163	198	82%
Zhadnova	2020	Number of PWTB with sustained engagement with the DAT after 6 months.		15	44	34%

PWTB person with TB ; VST video-supported therapy; DAT digital adherence technology

Doi plot showing study asymmetry





Doi plots and the Luis Furuya-Kanamori (LFK) index are alternatives to the funnel plot for assessing publication bias in a meta-analysis of proportions. Doi plots show normal quantile against effect size. When plotted, we can visually assess the symmetry (or assymmetry) in the effect estimates of studies, with each dot representing an individual study. Our a priori expectation is that studies showing higher levels of treatment adherence would be more likely to be published. Due to the high variability in measures included in this review, we assessed publication bias by evaluating similar non-engagement measures where the non-engagement threshold was >90% [18 data points]. When interpreting the LFK index, utilized to quantify asymmetry of small study effects from the Doi plot. With a LFK index less than +/-2 (-0.77) we do not find evidence of major asymmetry or publication bias [1,2].

Table S9: Summary of technological challenges in DAT implementation

DAT type	Person/system	author (year)	Description	n/N	%	Additional notes
SMS	Person with TB	Hermans (2017)	% of persons with TB who had phone issues (stolen, not able to charge battery, damaged phone, no longer access to shared phone)	45/171	26%	
	System	Gashu (2021)	% of persons with TB who received no messages	4/152	3%	
		Gashu (2021)	% SMS messages not delivered		15%	
		Dessie Gashu (2020)	% of persons with TB who did not receive all reminders (over 2 months)	3/23	13%	
		Mohammed (2016)	% reminders not sent or received	46276/220560	21%	
		Hermans (2017)	% of persons with TB who did not receive all reminders	16/171	9%	
		Mohammed (2016)	of reminders not received, % due to system failures, GPRS (General Packet Radio Service) outage		67%	
Phone	Person with TB	Daftary (2017)	% of calls that failed due to PIN failure	304/2867	11%	interactive voice response - messages sent, person with TB needed a PIN code to answer
		Katende (2022)	% of voice messages not received by person with TB	4/27	15%	Probably due to phone switched off
	System	Daftary (2017)	% of calls that failed due to network malfunction	540/2867	19%	
		Katende (2022)	% SMS not received by person with TB	8/103	8%	(listed under phone as it was the main DAT component)

99DOTS	person with TB	Kiwanuka (2022)	% SMS received on handsets of people with TB, of all reminders sent	58547/58831	99.50%	
		Efo (2021)	% of persons with TB who could not call back at least once due to lack of phone credit	58/200	29%	
	НСР	Kiwanuka (2022)	% SMS reminders sent among eligible days	58831/65045	90.40%	
		Guzman (2023)	% HCP who could not access adherence data due to no electricity, poor network, App not working (at any point)	41/70	59%	
		Guzman (2023)	% HCP who received DAT data daily	56/61	92%	
		Guzman (2023)	Of HCPs who cannot access adherence data, the % due to poor network connection	34/41	83%	
		Guzman (2023)	Of HCPs who cannot access adherence data, the % due to App not working	33/41	80%	
	System	Kiwanuka (2022)	% days with SMS sending failure due to service outage	29/357	8.12%	
Pillbox	Person with TB	Liu (2015)	% of all active pillbox problems due to incorrect pillbox use by person with TB	429/1610	27%	
		Liu (2015)	% of all active pillbox problems due to no power	537/1610	33%	
	System	Liu (2015)	% of persons with TB who experienced any DAT problem (e.g., incorrect setting, lack of power, failure, other issues)	1003/2061	49%	reasons were multiple
		Liu (2015)	% of all active pillbox problems for which the pillbox had to be replaced	284/1610	18%	
		Liu (2015)	% of all active pillbox problems due to pillbox failure	440/1610	27%	

Liu (2023)	% error days	2812/193,200	1%	
Trajman (2010)	% of persons with TB with incomplete pillbox data	126/802	16%	reasons included loss/destruction of bottles; problems with the electronic device; repeat openings of box
				Reasons for missing pillbox data include incorrect usage by HCP/person with TB; person with TB did not bring pillbox to clinic;
Wang (2020)	% doses with missing instances of pillbox data	1526/6381	24%	person with TB did not attend visit
Acosta (2022)	% of persons with TB who incorrectly did not receive SMS at least once	9/49	18%	
Acosta (2022)	% of persons with TB who incorrectly did receive SMS at least once	37/49	76%	
de Sumari-de Boer (2016)	of reminders sent, % that were incorrect (median across 5 persons with TB)		75%	
de Sumari-de Boer (2016)	of reminder sent, % not received on phone	46/500	9%	
Guzman (2023)	% HCP who could not access adherence data due to no electricity, poor network, App not working	6/20	30%	
Guzman (2023)	% HCP who received DAT data daily	17/20	85%	
Liu (2015)	% of all active pillbox problems due to doctor setting active pillbox incorrectly	3/1610	0.2%	
Liu (2015)	% of all active pillbox problems that were resolved	1425/1610	89%	
Guzman (2023)	Of those who cannot access adherence data, the % due to poor network connection	4/6	67%	

		Guzman (2023)	Of those who cannot access adherence data, the % due to App not working	1/6	17%
VST	person with TB	Guo (2020)	% of persons with TB with problems uploading videos/app>10% of time	26/235	11%
		Chuck (2016)	% of persons with TB with technical problems using VST	54/61	89%
		Hoffman (2010)	% expected videos not received due to lost phone		10%
		Nguyen (2017)	% of persons with TB with problems using VST platform	16/40	40%
		Garfein (2018)	% of persons with TB experiencing any problem with application	132/214	62%
		Garfein (2018)	% of persons with TB experiencing problem with application >half the time	10/132	8%
		Casalme (2022)	% persons with TB who stopped VST due to technology challenges	7/22	32%
		Chuck (2016)	of problems, % due to technical issues (overall)	276/316	87%
		Chuck (2016)	of problems, % due to person with TB-related smart-phone issues	40/316	13%
		Sekandi (2020)	of videos not transmitted, % due to phone issues	616/919	67%
		Sekandi (2020)	of videos not transmitted, % due to phone malfunction	293/919	32%
		Sekandi (2020)	of videos not transmitted, % due to phone battery issues	223/919	24%
		Sekandi (2020)	of videos not transmitted, % due to App issues	97/919	11%
		Sekandi (2020)	of videos not transmitted, % due to lack of internet	48/919	5%

	System	Garfein (2018)	% of persons with TB experiencing any cellphone reception issue	147/212	69%	
		Garfein (2018)	% of persons with TB experiencing cellphone reception issue> half the time	20/147	14%	
		Hoffman (2010)	% expected videos not received due to technical issues with transmission		25%	
		Hoffman (2010)	% expected videos not received		50%	
		Chuck (2016)	of all problems, % due to slow internet	72/316	23%	
		Sekandi (2020)	of videos not transmitted, % due to lack of internet	48/919	5%	
	НСР	Guo (2020)	% HCP not satisfied with the quality of videos	8/56	12%	
		Guo (2020)	% HCP who experience problems with the app >10% of the time	3/66	5%	
		Bendiksen (2020)	% HCP who reported problems with video DAT	5/17	29%	
		Bendiksen (2020)	% days that video conferencing not undertaken due to technical issues	268/3023	9%	unclear if from person with TB or HCP side or both
		Krueger (2010)	% video calls where there were technical difficulties experienced	73/4420	2%	unclear if from person with TB or HCW side or both
Ingestible sensor		Belknap	% sensor-days where wearable component was not working	34/1080	3.1%	
		Belknap	% of sensors not identified correctly by the system (issue of wearable component/sensor functioning	54/1080	5.0%	

PWTB person with TB; HCP health care provider; SMS short message service; DAT digital adherence technology; PIN personal identification number; VST video-supported therapy

Author (year)	DAT (primary)	Description	n/N	%
Liu (2015)	SMS	% of participants who started intensive management, of those eligible	40/265	15.1%
Liu (2015)	SMS	% of participants who started DOT management, of those eligible	8/357	2.2%
Liu (2015)	pillbox	% of participants who started intensive management, of those eligible	32/162	19.8%
Liu (2015)	pillbox	% of participants who started DOT management, of those eligible	9/240	3.8%
Liu (2015)	SMS&pillbox	% of participants who started intensive management, of those eligible	44/170	25.9%
Liu (2015)	SMS&pillbox	% of participants who started DOT management, of those eligible	10/214	4.7%
Wang (2020)	pillbox	% of participants who started DOT management, of those eligible	29/134	21.6%
Kiwanuka (2022)	99DOTS	% of participants who reported their HCP contacted them, when eligible	60/83	72.3%
Kiwanuka (2022)	99DOTS	% of participants who received at least one type of support action among those eligible	261/409	63.8%
Kumwichar (2022)	VST	% of dose-days when a reminder was sent, of eligible dose-days	32/72	44.4%
Wei* (2023)	pillbox	% of participants who received VST, of those eligible - month 1	2/2	100.0%
Wei* (2023)	pillbox	% of participants who received VST, of those eligible - month 2	2/2	100.0%
Wei* (2023)	pillbox	% of participants who received VST, of those eligible - month 3	11/12	91.7%
Wei* (2023)	pillbox	% of participants who received VST, of those eligible - month 4	17/18	94.4%
Wei* (2023)	pillbox	% of participants who received VST, of those eligible - month 5	21/23	91.3%
Wei* (2023)	pillbox	% of participants who received VST, of those eligible - month 6	39/44	88.6%
Liu (2023)	pillbox	% of participants who were reported as receiving intensive management, of those eligible	156/190	82.1%
Liu (2023)	pillbox	% of participants who were reported as receiving DOT management, of those eligible	53/99	53.5%
Bassett (2016)	SMS	% of participants who received >=5 call attempts, as required by protocol	694/967	71.8%

Table S9: Summary of provider fidelity for DAT implementation

SMS short message service; VST video-supported therapy; DOT directly observed therapy; HCP health care provider. "Participants" here reflects persons with TB

* Wei study was included as a preprint (2023), though these data were abstracted from the supplement of the subsequently published article (2024) [3,4].

Table S10. Summary of included reports by DAT type, RE-AIM indicators, country income level, and calendar year by first author and publication year (n=105)

	НІС								L/LMIC			
	2000-2017		2018-2023			2000-2017		2018-2023		2000-2017		2018-2023
	n	RE-AIM	n	RE-AIM	n	RE-AIM	n	RE-AIM	n	RE-AIM	n	RE-AIM
SMS	-		1	Johnston (2018)	3	Bassett (2016); Lei (2013); Iribarren (2013)	2	Louwagie (2022); Khachadourian (2020)	3	Mohammed (2016); Mohammed (2012); Hermans (2017)	3	Cox (2018); Musiimenta (2020); Gashu (2021)
phone	1	Person (2011)	-		-		5	Iribarren (2022); Zhadnova (2020); l (2019); Li (2022); Saunders (2018)	3	Daftary (2017); Narasimhan (2014); Kittusami (2014)	11	Kalita (2021); Gashu (2021); Katende (2022); Santra (2021); Rao (2022); Ali (2019); Jose (2022); Mathur (2019); Kumar (2019); Ggita (2018); Gashu (2020)
99DOTS	-		-		-		-		-		7	Thakkar (2019); Cross (2019); Kiwanaku (2022); Cattamanchi (2021); Efo (2021); Subbaraman (2021); Thomas (2020)
Pillbox	4	Belknap (2017); Trajman (2010); Menzies (2005); Ailinger (2008)	3	Wei (2023); O'Donnell (2022); Scott (2023)	-		9	Zelnick (2021); Ratchakit-Nedsuwan (2020); Wang (2019); Wang (2020); Guo (2021); Wei (2023); Liu (2023); Acosta (2022); Wang (2021)	3	de Sumari-de Boer (2016); Moulding (2002); van den Boogaard (2011)	4	Park (2019); Velen (2023); Muyindike (2022); Manyazewal (2022)
VST	9	Demaio (2001); Garfein (2015); Olano-Soler (2017); Krueger (2010); Chuck (2016); Mirsaedi (2015); Wade (2009);	15	Holzman (2018); Zhao (2022); Bachina (2022); Garfein (2020); Rajalahti (2022); Lam (2018); Lippincott (2022); Macaraig (2018); Story (2019); Bendiksen (2020);	1	Sinkou (2017)	3	Kumwichar (2022); Guo (2020); Peinado (2022)	2	Nguyen (2017); Hoffman (2010)	4	Casalme (2022); Holzman (2019); Sekandi (2021); Sekandi (2020)

		Wade (2012); Buchman (2017)		Bommakanto (2020); Do (2019); Garfein (2018); Donahue (2021); Perry (2021)								
Ingestion sensor	1	Belknap (2013)	1	Browne (2019)	-		-		-		-	
Web-based Apps	-		1	Kim (2021)	-		1	Cocozza (2020)	1	Navin (2017)	2	Chen (2022); Adong (2022)
>1 DAT intervention	-		-		1	Liu (2015)	-		-		2	Guzman (2023); de Groot (2022)

2.2.2. References from which data were extracted for the scoping review

The numbering does not relate to reference numbers in the main manuscript. 106 articles listed – 105 included in the review plus Wei 2024 for which the data from the supplement was used in the review.

1) Cross A. 99DOTS: A low-cost approach to monitoring and improving medication adherence. ACM International Conference Proceeding Series. 2019.

2) Kim AJ, Yang J, Jang Y, Baek JS. Acceptance of an informational antituberculosis chatbot among Korean adults: mixed methods research. JMIR mHealth and uHealth. 2021;9: e26424.

3) Holzman SB, Zenilman A, Shah M. Advancing patient-centred care in tuberculosis management: a mixed-methods appraisal of video directly observed therapy. Open Forum Infect Dis. 2018;5.

4) DeMaio J, Schwartz L, Cooley P, Tice A. The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. Clin Infect Dis. 2001;33: 2082–2084.

5) Cocozza AM, Linh NN, Nathavitharana RR, Ahmad U, Jaramillo E, Gargioni GEM, et al. An assessment of current tuberculosis patient care and support policies in high-burden countries. International Journal of Tuberculosis and Lung Disease. 2020;24: 36–42.

6) O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, et al. Bedaquiline adherence measured by electronic dose monitoring predicts clinical outcomes in the treatment of patients with multidrug-resistant tuberculosis and HIV/AIDS. Journal of acquired immune deficiency syndromes (1999). 2022.

7) Do D, Garfein RS, Cuevas-Mota J, Collins K, Liu L. Change in Patient Comfort Using Mobile Phones Following the Use of an App to Monitor Tuberculosis Treatment Adherence: Longitudinal Study. JMIR MHealth UHealth. 2019;7: 11638.

8) Guo X. A comprehensive app that improves tuberculosis treatment management through video-observed therapy: usability study. JMIR Mhealth Uhealth. 2020;8.

9) Narasimhan P. A customized m-health system for improving tuberculosis treatment adherence and follow-up in South India. Health Technol. 2014;4: 1–10.

10) Dessie Gashu K, Nurhussien F, Mamuye A, Alemu Gelaye K, Tilahun B. Developing and Piloting TB Medication and Refilling Reminder System in Ethiopia. Studies in health technology and informatics. 2020;270: 1251–1252.

11) Cattamanchi A. Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. PLoS Medicine. 2021;18: 1–15.

12) Guo G, Sun L, Wushoue Q, Jia B, Yusufu M, Wen S, et al. eDOTS: a new system applied for improving the treatment of pulmonary tuberculosis patients from Kashgar villages and Urumqi streets in Xinjiang, China. In Review; 2021 Mar.

13) Louwagie G, Kanaan M, Morojele NK, Van Zyl A, Moriarty AS, Li J, et al. Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in South Africa. BMJ Open. 2022;12: e056496.

14) Santra S, Garg S, Basu S, Sharma N, Singh M, Khanna A, et al. The effect of a mhealth intervention on anti-tuberculosis medication adherence in Delhi, India: A quasi-experimental study. Indian Journal of Public Health. 2021;65: 34–38.

15) Gashu KD, Gelaye KA, Lester R, Tilahun B. Effect of a phone reminder system on patient-centered tuberculosis treatment adherence among adults in Northwest Ethiopia: a randomised controlled trial. BMJ health & care informatics. 2021;28.

16) Johnston JC. The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. Eur Respir J. 2018;51.

17) Wang XL, Lei J, Wang XW, Liu T, Lu JR, Tian XM. Construction and effect evaluation of tuberculosis information platform in Ningxia. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2021;55: 517–520.

18) Liu X. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster randomised trial. PLoS Med. 2015;12.

19) Zelnick JR, Daftary A, Hwang C, Labar AS, Boodhram R, Maharaj B, et al. Electronic dose monitoring identifies a high-risk subpopulation in the treatment of drug-resistant tuberculosis and human immunodeficiency virus. Clinical infectious diseases: an official publication of the infectious diseases society of America. 2021;73: e1901–e1910.

20) Wang N. Electronic medication monitor for people with tuberculosis: Implementation experience from thirty counties in China. PLoS ONE. 2020;15: 1–14. 21) van den Boogaard J, Lyimo R, Boeree M, Kibiki G, Aarnoutse R. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Org. 2011;89: 632–640.

22) Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with Video Directly Observed Therapy in New York City. The International Journal of Tuberculosis and Lung Disease. 2016;20: 588–593.

23) Ratchakit-Nedsuwan R. Ensuring tuberculosis treatment adherence with a mobilebased CARE-call system in Thailand: a pilot study. Infect Dis. 2020;52: 121–129.

24) Li F, Tian Z, Bobb J, Papadogeorgou G, Li F. Clarifying selection bias in cluster randomized trials. Clinical Trials. 2022;19: 33–41.

25) Garfein RS, Liu L, Cuevas-Mota J, Collins K, Catanzaro DG, Munoz F, et al. Evaluation of recorded video-observed therapy for anti-tuberculosis treatment. International Journal of Tuberculosis and Lung Disease. 2020;24: 520–525.

26) Thomas BE. Evaluation of the accuracy of 99DOTS, a novel cellphone- based strategy for monitoring adherence to tuberculosis medications: comparison of digital adherence data with urine Isoniazid testing'. Clinical Infectious Diseases. 2020;71: 513–516.

27) Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. International journal of tuberculosis and lung disease. 2010;14: 551-559.

28) Kalita J, Pandey PC, Shukla R, Misra UK. Feasibility and usefulness of tele-follow-up in the patients with tuberculous meningitis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2021;115: 1153–1159.

29) Belknap R, Weis S, A B. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013;8:e53373.

30) de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, Semvua HH, Kiwango KW, Aarnoutse RE, et al. Feasibility of real time medication monitoring among HIV infected and TB patients in a resource-limited setting. AIDS and behavior. 2016;20: 1097–1107.

31) Garfein RS. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis. 2015;19: 1057–1064.

32) Gashu KD, Gelaye KA, Tilahun B. Feasibility, acceptability and challenges of phone reminder system implementation for tuberculosis pill refilling and medication in Northwest Ethiopia. 2021.

33) Wade VA. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS One. 2012;7.

34) Mohammed S, Glennerster R, Khan AJ. Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: a randomized controlled trial. Gao L, editor.

35) Menzies D, Dion MJ, Francis D, Parisien I, Rocher I, Mannix S, et al. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. International Journal of Tuberculosis and Lung Disease. 2005;9: 1343–1348.

36) Lei X, Liu Q, Wang H, Tang X, Li L, Wang Y. Is the short messaging service feasible to improve adherence to tuberculosis care? A cross-sectional study. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2013;107: 666–668.

37) Kittusami SP, Gurumurthy G, Prashant S, Rangarajan J, leee, Technol, et al. Leveraging mobile phones for facilitating treatment adherence among patients with chronic health conditions implementation results with tuberculosis as case study. 2nd IEEE Region10 Humanitarian Technology Conference (R10 HTC). 2014; 99–104.

38) Moulding TS, Caymittes M. Managing medication compliance of tuberculosis patients in Haiti with medication monitors. Int JTuberc Lung Dis. 2002;6: 313–319.

39) Subbaraman R, Thomas BE, Kumar JV, Thiruvengadam K, Khandewale A, Kokila S, et al. Understanding nonadherence to tuberculosis medications in India using urine drug metabolite testing: a cohort study. Open Forum Infectious Diseases. 2021;8: ofab190.

40) Park S, Sentissi I, Gil SJ, Park WS, Oh B, Son AR, et al. Medication event monitoring system for infectious tuberculosis treatment in Morocco: a retrospective cohort study. International Journal of Environmental Research & Public Health [Electronic Resource]. 2019;16: 31.

41) Hoffman JA. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. Am J Prev Med. 2010;39: 78–80.

42) Kumar AA. Mobile health for tuberculosis management in South India: Is videobased directly observed treatment an acceptable alternative?'. JMIR mHealth and uHealth. 2019;7.

43) Navin K, Vadivu G, Maharaj A, Thomas T, Lavanya S, Engn, et al. A mobile health intervention to support TB eradication programme for adherence to treatment and a novel

QR code-based technique to monitor patient-DOTS provider interaction. 1st International Conference on Advanced Computational and Communication Paradigms (ICACCP). 2017;475: 41–54.

44) Musiimenta A, Tumuhimbise W, Atukunda EC, Mugaba AT, Muzoora C, Armstrong-Hough M, et al. Mobile health technologies may be acceptable tools for providing social support to tuberculosis patients in rural Uganda: A parallel mixed-method study. Tuberculosis Research & Treatment Print. 2020;2020: 7401045.

45) Ali AOA, Prins MH. Mobile health to improve adherence to tuberculosis treatment in Khartoum state, Sudan. J Public Health Africa. 2019;10.

46) Cox SN, Elf J, Lokhande R, Ogale YP, DiAndreth L, Dupuis E, et al. Mobile phone access and comfort: Implications for HIV and tuberculosis care in India and South Africa. Open Forum Infectious Diseases. 2018;5: S162.

47) Saunders MJ, Wingfield T, Tovar MA, Herlihy N, Rocha C, Zevallos K, et al. Mobile phone interventions for tuberculosis should ensure access to mobile phones to enhance equity - a prospective, observational cohort study in Peruvian shantytowns. Trop Med Int Health. 2018;23: 850–859.

48) Zhdanova SN, Ogarkov OB, Heysell SK. Mobile health intervention for outpatient treatment of Tuberculosis and HIV Infection. Acta biomedica scientifica. 2020;5: 46–53.

49) MaCaraig M, Lobato MN, McGinnis Pilote K, Wegener D. A national survey on the use of electronic directly observed therapy for treatment of tuberculosis. J Public Heal Manag Pract. 2018.

50) Buchman T, Cabello C. A new method to directly observed tuberculosis treatment: Skype observed therapy, a patient-centered approach. Journal of public health management and practice : JPHMP. 2017;23: 175–177.

51) Olano-Soler H, Thomas D, Joglar O, Rios K, Torres-Rodriguez M, Duran-Guzman G, et al. Notes from the Field: Use of asynchronous video directly observed therapy for treatment of Tuberculosis and Latent Tuberculosis infection in a long-term-care facility - Puerto Rico, 2016-2017. MMWR Morbidity and mortality weekly report. 2017;66: 1386–1387.

52) Ggita JM, Ojok C, Meyer AJ, Farr K, Shete PB, Ochom E, et al. Patterns of usage and preferences of users for tuberculosis-related text messages and voice calls in Uganda. International Journal of Tuberculosis and Lung Disease. 2018;22: 530–536.

53) Khachadourian V, Truzyan N, Harutyunyan A, Petrosyan V, Davtyan H, Davtyan K, et al. People-centred care versus clinic-based DOT for continuation phase TB treatment in Armenia: a cluster randomized trial. BMC pulmonary medicine. 2020;20: 105.

54) Thakkar D, Piparva K, Lakkad S. A pilot project: 99DOTS information communication technology-based approach for tuberculosis treatment in Rajkot district. Lung India. 2019;36: 108.

55) Daftary A, Hirsch-Moverman Y, Kassie G, Melaku Z, Gadisa T, Saito S, et al. A qualitative evaluation of the acceptability of an interactive voice response system to enhance adherence to Isoniazid preventive therapy among people living with HIV in Ethiopia. AIDS & Behavior. 2017;21: 3057–3067.

56) Acosta J, Flores P, Alarcon M, Grande-Ortiz M, Moreno-Exebio L, Puyen ZM. A randomised controlled trial to evaluate a medication monitoring system for TB treatment. International journal of tuberculosis and lung disease. 2022;26: 44-49.

57) Perry A, Chitnis A, Chin A, Hoffmann C, Chang L, Robinson M, et al. Real-world implementation of video-observed therapy in an urban TB program in the United States. International Journal of Tuberculosis and Lung Disease. 2021;25: 655–661.

58) Bommakanti KK, Smith LL, Liu L, Do D, Cuevas-Mota J, Collins K, et al. Requiring smartphone ownership for mHealth interventions: who could be left out? BMC public health. 2020;20: 81.

59) Belknap R. Self-administered versus directly observed once-weekly isoniazid and Rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167: 7326 17–1150.

60) Bassett I. Sizanani: a randomized trial of health system navigators to improve linkage to HIV and TB care in South Africa. J Acquir Immune Defic Syndr. 2016;73: 154–160.

61) Story A. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet. 2019;393: 1216–1224.

62) Sekandi JN, Onuoha NA, Buregyeya E, Zalwango S, Kaggwa PE, Nakkonde D, et al. Using a Mobile Health Intervention (DOT Selfie) With Transfer of Social Bundle Incentives to Increase Treatment Adherence in Tuberculosis Patients in Uganda: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2021;10: e18029.

63) Mathur A, Bhowmick S, Sorathia K, Emerging Technologies S, Indian Inst Technol Iit Guwahati EILGI, Int Federat Informat Proc Tech Comm. A Study of Outbound Automated Call Preferences for DOTS Adherence in Rural India. 17th IFIP TC13 International Conference on Human-Computer Interaction (INTERACT). 2019;11748: 24–33. 64) Donahue ML, Eberly MD, Rajnik M. Tele-TB: Using TeleMedicine to Increase Access to Directly Observed Therapy for Latent Tuberculosis Infection. Military medicine. 2021;186: 25–31.

65) Zhao A, Butala N, Luc CM, Feinn R, Murray TS. Telehealth Reduces Missed Appointments in Pediatric Patients with Tuberculosis Infection. Tropical Medicine and Infectious Disease. 2022;7: 26.

66) Person AK, Blain ML, Jiang H, Rasmussen PW, Stout JE. Text messaging for enhancement of testing and treatment for tuberculosis, human immunodeficiency virus, and syphilis: a survey of attitudes toward cellular phones and healthcare. Telemed J E Health. 2011;17: 189–95.

67) Hermans SM. Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda. Patient Prefer Adherence. 2017;11: 1479–1487.

68) Iribarren S. TextTB: a mixed method pilot study evaluating acceptance, feasibility, and exploring initial efficacy of a text messaging intervention to support TB treatment adherence. Tuberc Res Treat. 2013;2013.

69) Garfein RS, Lin L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, et al. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerging Infectious Diseases. 2018;24: 1806–1815.

70) Ailinger RL, Black PL, Lima-Garcia N. Use of electronic monitoring in clinical nursing research. Clinical Nursing Research. 2008;17: 89–97.

71) Holzman SB. Use of smartphone-based video directly observed therapy (vDOT) in tuberculosis care: single-arm, prospective feasibility study. JMIR Form Res. 2019;3: 13411.

72) Bendiksen R, Ovesen T, Asfeldt AM, Halvorsen DS, Gravningen K. Use of video call in the treatment of tuberculosis disease in Northern Norway. Tidsskrift for Den Norske Laegeforening. 2020;140: 35–40.

73) Mohammed S, Siddiqi O, Ali O, Habib A, Haqqi F, Kausar M, et al. User engagement with and attitudes towards an interactive SMS reminder system for patients with tuberculosis. J Telemed Telecare. 2012;18: 404–408.

74) Wang N. Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China'. BMC Infectious Diseases. 2019;19: 1–9.

75) Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: An implementation study. J Med Internet Res. 2018.

76) Sekandi JN. Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study. ERJ Open Res. 2020;6: 00175–02019.

77) Mirsaeidi M, Farshidpour M, Banks-Tripp D, Hashmi S, Kujoth C, Schraufnagel D. Video directly observed therapy for treatment of tuberculosis is patient-oriented and costeffective. European Respiratory Journal. 2015;46: 871–874.

78) Nguyen TA, Pham MT, Nguyen TL, Nguyen VN, Pham DC, Nguyen BH, et al. Video Directly Observed Therapy to Support Adherence with Treatment for Tuberculosis in Vietnam: A Prospective Cohort Study. International Journal of Infectious Diseases. 2017;65: 85–89.

79) Sinkou H, Hurevich H, Rusovich V, Zhylevich L, Falzon D, De Colombani P, et al. Videoobserved treatment for tuberculosis patients in Belarus: Findings from the first programmatic experience. European Respiratory Journal. 2017;49: 1602049.

80) Wade VA, Karnon J, Eliott JA, Hiller JE. Home Videophones Improve Direct Observation in Tuberculosis Treatment: A Mixed Methods Evaluation. PLoS ONE. 2012;7: e50155.

81) Krueger K, Ruby D, Cooley P, Montoya B, Exarchos A, Djojonegoro BM, et al. Videophone utilization as an alternative to directly observed therapy for tuberculosis. International Journal of Tuberculosis and Lung Disease. 2010;14: 779–781.

82) Browne SH, Umlauf A, AJ T. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLoS Med. 2019;16:e1002891.

83) Guzman K, Crowder R, Leddy A, Maraba N, Jennings L, Ahmed S, et al. Acceptability and feasibility of digital adherence technologies for tuberculosis treatment supervision: A meta-analysis of implementation feedback. 2023.

84) Jose NK, Vaz C, Chai PR, Rodrigues R. The Acceptability of Adherence Support via Mobile Phones for Antituberculosis Treatment in South India: Exploratory Study. JMIR formative research. 2022;6: e37124.

85) Rao JS, Diwan V, Kumar A, Varghese SS, Sharma U, Purohit M, et al. Acceptability of video observed treatment vs. directly observed treatment for tuberculosis: a comparative analysis between South and Central India. 2022.

86) Efo E, Onjare B, Shilugu L, Levy J, Ieee, Kncv Tb Fdn MNLABTHABN, et al. Acceptability, Feasibility and Accuracy of 99DOTS Adherence Technology in Mining Region of Tanzania. IST-Africa Conference (IST-Africa). 2021.

87) Rajalahti I, Kreivi HR, Ollgren J, Vasankari T. Asynchronous video supported treatment of tuberculosis is well adopted in a real-world setting - an observational study comparing two distinct applications. Infectious diseases (London, England). 2022; 04-Jan.

88) Adong J, Fatch R, Emenyonu N, Muyindike W, Ngabirano C, Cheng D, et al. Cell Phone Availability and Usage for mHealth and Intervention Delivery to Persons Living With HIV in a Low-Resource Setting: Cross-sectional Study. JMIR formative research. 2022;6: e35631.

89) Katende KK, Amiyo MR, Nabukeera S, Mugisa I, Kaggwa P, Namatovu S, et al. Design, development, and testing of a voice-text mobile health application to support Tuberculosis medication adherence in Uganda. PloS one. 2022;17: e0274112.

90) Liu X, Thompson J, Dong H. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health. 2023;11: 693–703.

91) Velen K, Nguyen TA, Pham CD, Le HT, Nguyen HB, Dao BT, et al. The effect of medication event reminder monitoring on treatment adherence of TB patients. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2023;27: 322–328.

92) Manyazewal T, Woldeamanuel Y, Holland DP, Fekadu A, Marconi VC. Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial. BMC medicine. 2022;20: 310.

93) Casalme DJO, Marcelo DB, Dela Cuesta DM, Tonquin M, Frias MVG, Gler MT. Feasibility and acceptability of asynchronous VOT among patients with MDR-TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2022;26: 760–765.

94) Chen A, Kumar R, Baria RK, Shridhar PK, Subbaraman R, Thies W. Impact of the 99DOTS digital adherence technology on tuberculosis treatment outcomes in North India: a pre-post study. 2022.

95) Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger C, Lamunu M, et al. Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda. 2022. 96) Iribarren SJ, Milligan H, Chirico C, Goodwin K, Schnall R, Telles H, et al. Patientcentered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs. Lancet regional health Americas. 2022;13.

97) Bachina P, Lippincott CK, Perry A, Munk E, Maltas G, Bohr R, et al. Programmatic adoption and implementation of video-observed therapy in Minnesota: prospective observational cohort study. JMIR formative research. 2022;6: e38247.

98) de Groot LM, Straetemans M, Maraba N, Jennings L, Gler MT, Marcelo D, et al. Time trend analysis of tuberculosis treatment while using digital adherence technologies: an individual patient data meta-analysis of eleven projects across ten high tuberculosis-burden countries. Tropical Medicine and Infectious Disease. 2022;7: 65.

99) Lippincott CK, Perry A, Munk E, Maltas G, Shah M. Tuberculosis treatment adherence in the era of COVID-19. BMC Infectious Diseases. 2022;22: 800.

100) Muyindike WR, Fatch R, Cheng DM, Emenyonu NI, Forman L, Ngabirano C, et al. Unhealthy alcohol use Is associated with suboptimal adherence to isoniazid preventive therapy in persons with HIV in Southwestern Uganda. Journal of Acquired Immune Deficiency Syndromes. 2022;91: 460–468.

101) Scott AA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, et al. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemporary clinical trials. 2023; 107173.

102) Peinado J, Tamaki J, Yataco R, Pages G, Arrospide A, Rimac A, et al. Video supervised treatment of patients with pulmonary tuberculosis in a health care center in Lima. Pilot study. Revista Medica Herediana. 2022;33: 14-Sep.

103) Kumwichar P, Chongsuvivatwong V, Prappre T. Video-observed therapy with a notification system for improving the monitoring of tuberculosis treatment in Thailand: usability study. JMIR formative research. 2022;6: e35994.

104) Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. The Lancet. 2024; S0140673623022705. doi:10.1016/S0140-6736(23)02270-5

105) I NH, Juni MH. Effectiveness of health education module delivered through Whatsapp to enhance treatment adherence and successful outcome of tuberculosis in Seremban district, Negeri Sembilan, Malaysia. International journal of public health & clinical sciences (IJPHCS). 2019;6: 145-159. 106) Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a comprehensive package-based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: A multi-centre randomised controlled trial. 2023.

2.3. Supplement references

- Shamim MA. Real-life implications of prevalence meta-analyses? Doi plots and prediction intervals are the answer. The Lancet Microbe. 2023;4: e490. doi:10.1016/S2666-5247(23)00096-4
- 2. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol. 2014;67: 897–903. doi:10.1016/j.jclinepi.2014.03.003
- Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a Comprehensive Package Based on Electronic Medication Monitors at Improving Treatment Outcomes Among Tuberculosis Patients in Tibet: A Multi-Centre Randomised Controlled Trial. 2023. doi:10.2139/ssrn.4387313
- 4. Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. The Lancet. 2024; S0140673623022705. doi:10.1016/S0140-6736(23)02270-5